CN110114357B - 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物 - Google Patents

可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物 Download PDF

Info

Publication number
CN110114357B
CN110114357B CN201780080803.4A CN201780080803A CN110114357B CN 110114357 B CN110114357 B CN 110114357B CN 201780080803 A CN201780080803 A CN 201780080803A CN 110114357 B CN110114357 B CN 110114357B
Authority
CN
China
Prior art keywords
alkyl
hydrogen
substituted
heteroatoms selected
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780080803.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110114357A (zh
Inventor
S·T·弗罗布莱斯基
D·S·温斯坦
M·G·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN110114357A publication Critical patent/CN110114357A/zh
Application granted granted Critical
Publication of CN110114357B publication Critical patent/CN110114357B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201780080803.4A 2016-10-28 2017-10-27 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物 Active CN110114357B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414158P 2016-10-28 2016-10-28
US62/414,158 2016-10-28
PCT/US2017/058645 WO2018081488A1 (en) 2016-10-28 2017-10-27 Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (2)

Publication Number Publication Date
CN110114357A CN110114357A (zh) 2019-08-09
CN110114357B true CN110114357B (zh) 2022-05-31

Family

ID=60263169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080803.4A Active CN110114357B (zh) 2016-10-28 2017-10-27 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物

Country Status (8)

Country Link
US (1) US10781215B2 (enExample)
EP (1) EP3532473B1 (enExample)
JP (1) JP7145850B2 (enExample)
KR (1) KR102477063B1 (enExample)
CN (1) CN110114357B (enExample)
ES (1) ES2895107T3 (enExample)
MA (1) MA46620A (enExample)
WO (1) WO2018081488A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
AR117177A1 (es) * 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
CN113874021B (zh) * 2019-03-26 2024-07-09 温缇克斯生物科学公司 Tyk2假激酶配体
CN114269336A (zh) 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
AU2020378345A1 (en) 2019-11-08 2022-06-02 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
US11697648B2 (en) * 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
CN116283993B (zh) * 2021-12-20 2024-05-03 艾立康药业股份有限公司 一种嘧啶类化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009131687A2 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN104903301A (zh) * 2012-11-08 2015-09-09 百时美施贵宝公司 可用于调节IL-12、IL-23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
ES2424977T3 (es) 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
RU2016148863A (ru) 2014-05-14 2018-06-18 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт Гетероциклические гидроксамовые кислоты в качестве ингибиторов протеин-деацетилазы и двойных ингибиторов протеин-деацетилазы-протеин-киназы и способы их применения
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009131687A2 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN104903301A (zh) * 2012-11-08 2015-09-09 百时美施贵宝公司 可用于调节IL-12、IL-23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors;Pierre-Yves Michellys等;《Bioorganic & Medicinal Chemistry Letters》;20160101;第26卷(第3期);第1092页 *

Also Published As

Publication number Publication date
MA46620A (fr) 2021-05-26
ES2895107T3 (es) 2022-02-17
WO2018081488A1 (en) 2018-05-03
EP3532473B1 (en) 2021-09-29
US20190322672A1 (en) 2019-10-24
EP3532473A1 (en) 2019-09-04
US10781215B2 (en) 2020-09-22
JP7145850B2 (ja) 2022-10-03
JP2019532092A (ja) 2019-11-07
CN110114357A (zh) 2019-08-09
KR20190068614A (ko) 2019-06-18
KR102477063B1 (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
CN110114357B (zh) 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物
CN111936486B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
KR102531036B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CN105992768B (zh) 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
KR102233252B1 (ko) ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
EP4143180A1 (en) Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
CN106660960A (zh) 用作IL‑12、IL‑23和/或IFNα响应的调节剂的烷基‑酰胺‑取代的吡啶化合物
CN110267964B (zh) 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物
CN113365982A (zh) 酰胺二取代的吡啶或哒嗪化合物
CN104903301A (zh) 可用于调节IL-12、IL-23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
CN117279906A (zh) 经取代的杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant